

## Datasheet: MCA1590SBV570

**BATCH NUMBER 100008295**

<b>Description:</b>	MOUSE ANTI HUMAN CD40:StarBright Violet 570
<b>Specificity:</b>	CD40
<b>Format:</b>	StarBright Violet 570
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	LOB7/6
<b>Isotype:</b>	IgG2a
<b>Quantity:</b>	100 TESTS/0.5ml

### Product Details

#### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

#### Target Species

Human

#### Species Cross Reactivity

Reacts with: Dog

**N.B.** Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.

#### Product Form

Purified IgG conjugated to StarBright Violet 570 - liquid

#### Max Ex/Em

Fluorophore	Excitation Max (nm)	Emission Max (nm)
StarBright Violet 570	404	571

#### Preparation

Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant

#### Buffer Solution

Phosphate buffered saline

<b>Preservative</b>	0.09% Sodium Azide (NaN <sub>3</sub> )
<b>Stabilisers</b>	1% Bovine Serum Albumin 0.1% Pluronic F68 0.1% PEG 3350 0.05% Tween 20
<b>Immunogen</b>	CD40 Ig(Fc) fusion protein containing the EC region of human CD40 and Fc region of human IgG.
<b>External Database Links</b>	<b>UniProt:</b> <a href="#">P25942</a> <a href="#">Related reagents</a>  <b>Entrez Gene:</b> <a href="#">958</a> CD40 <a href="#">Related reagents</a>
<b>Synonyms</b>	TNFRSF5
<b>Fusion Partners</b>	Spleen cells from immunised BALB/c mice were fused with cells of the mouse NS1 myeloma cell line.
<b>Specificity</b>	<b>Mouse anti Human CD40 antibody, clone LOB7/6</b> recognizes the human CD40 cell surface antigen, a 48kDa glycoprotein expressed by B lymphocytes and weakly by some monocytes.  CD40 is involved in the process of B cell selection in germinal centres and is vital in T cell-B cell interactions.
<b>Flow Cytometry</b>	Use 5µl of the suggested working dilution to label 10 <sup>6</sup> cells in 100µl. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
<b>References</b>	<ol style="list-style-type: none"> <li>1. Quadbeck, B. <i>et al.</i> (2002) Maturation of thyroidal dendritic cells in Graves' disease. <a href="#">Scand J Immunol. 55 (6): 612-20.</a></li> <li>2. Kirsch, B. M. <i>et al.</i> (2005) The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function. <a href="#">Arthritis Res. Ther. 7: R694-R703.</a></li> <li>3. Cheadle, E. <i>et al.</i> (2003) <i>Mycobacterium bovis</i> bacillus Calmette-Guerin-infected dendritic cells potently activate autologous T cells via a B7 and interleukin-12-dependent mechanism. <a href="#">Immunology.108: 79-88.</a></li> <li>4. Carpenter, E.L. <i>et al.</i> (2009) Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. <a href="#">J Transl Med. 7: 93.</a></li> <li>5. Garcia-Nieto, S. <i>et al.</i> (2010) Laminin and Fibronectin Treatment Leads to Generation of Dendritic Cells with Superior Endocytic Capacity. <a href="#">PLoS ONE. 5: 1-10.</a></li> <li>6. Wang, Y.S. <i>et al.</i> (2007) Characterization of canine monocyte-derived dendritic cells with phenotypic and functional differentiation. <a href="#">Can J Vet Res. 71: 165-74.</a></li> <li>7. Vlachoyiannopoulos, P.G. <i>et al.</i> (2004) Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus. <a href="#">Thromb Haemost. 92: 1303-11.</a></li> <li>8. Leigh, J.E. <i>et al.</i> (2006) Characterization of the immune status of CD8+ T cells in oral</li> </ol>

- lesions of human immunodeficiency virus-infected persons with oropharyngeal Candidiasis. [Clin Vaccine Immunol. 13: 678-83.](#)
9. Newman, K.C. *et al.* (2006) Cross-talk with myeloid accessory cells regulates human natural killer cell interferon-gamma responses to malaria. [PLoS Pathog. 2: e118.](#)
  10. Kuijf, M.L. *et al.* (2010) TLR4-mediated sensing of *Campylobacter jejuni* by dendritic cells is determined by sialylation. [J Immunol. 185: 748-55.](#)
  11. Huizinga R *et al.* (2015) Innate Immunity to *Campylobacter jejuni* in Guillain-Barré Syndrome. [Ann Neurol. 78 \(3\): 343-54.](#)
  12. Yildirim C *et al.* (2015) Galectin-2 induces a proinflammatory, anti-arteriogenic phenotype in monocytes and macrophages. [PLoS One. 10 \(4\): e0124347.](#)
  13. Brencicova, E. *et al.* (2017) Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma. [PLoS One. 12 \(4\): e0175712.](#)
  14. Silk, K.M. *et al.* (2012) Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype. [J Biomed Biotechnol. 2012: 172420.](#)
  15. Tischer, S. *et al.* (2011) Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies. [J Transl Med. 9: 175.](#)
  16. Unosson, J. *et al.* (2021) Acute cardiovascular effects of controlled exposure to dilute Petrodiesel and biodiesel exhaust in healthy volunteers: a crossover study. [Part Fibre Toxicol. 18 \(1\): 22.](#)
  17. Milhau, N. *et al.* (2020) *In vitro*. evaluations on canine monocyte-derived dendritic cells of a nanoparticles delivery system for vaccine antigen against *Echinococcus granulosus*. [PLoS One. 15 \(2\): e0229121.](#)
  18. Uetz-von Allmen, E *et al.* (2021) CAL-1 as Cellular Model System to Study CCR7-Guided Human Dendritic Cell Migration. [Front Immunol. 12: 702453.](#)

<b>Storage</b>	Store at +4°C. DO NOT FREEZE. This product should be stored undiluted.
<b>Guarantee</b>	12 months from date of despatch
<b>Acknowledgements</b>	This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #20471 available at: <a href="https://www.bio-rad-antibodies.com/SDS/MCA1590SBV570">https://www.bio-rad-antibodies.com/SDS/MCA1590SBV570</a> 20471
<b>Regulatory</b>	For research purposes only

## Related Products

### Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

'M426130:231121'

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

**Printed on 21 Feb 2024**

---

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)